Long-term efficacy of adalimumab in Paediatric Crohn's disease patients naïve to other anti-TNF therapies

Journal of Crohn's and Colitis

Volumn 4, Issue 5, 2010, Pages 594-598

  Martin de Carpi J ^a   Pociello, N ^b   Varea, V ^a  

^a HOSPITAL SANT JOAN DE DÉU   (Spain)

^b HOSPITAL ARNAU DE VILANOVA   (Spain)

Author keywords

Adalimumab; Anti TNF ; Children; Paediatric Crohn's disease

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARTICLE; CASE REPORT; CHILD; CHILDHOOD DISEASE; CROHN DISEASE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FAMILY HISTORY; FEMALE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; LOADING DRUG DOSE; MALE; MONOTHERAPY; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; TREATMENT RESPONSE;

6-MERCAPTOPURINE; ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHILD; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77958153818     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2010.04.002     Document Type: Article

References (24)

1. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial. Lancet 2002, 359:1541-1549.
2. Hyams J., Crandall W., Kugathasan S., Griffiths A., Olson A., Johanns J., et al. Induction and maintenance infliximab therapy for the treatment of of moderate-to-severe Crohn's disease in children. Gastroenterology 2007, 132:863-873.
3. Borrelli O., Bascietto C., Viola F., Bueno de Mesquita M., Barbato M., Mancini V., et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liv Dis 2004, 32:342-347.
4. Thayu M., Leonard M.B., Hyams J.S., Crandal W.V., Kugathasan S., Otley A.R., et al. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study. Clin Gastroenterol Hepatol 2008, 6:1378-1384.
5. Kugathasan S., Werlin S.L., Martínez A., Rivera M.T., Heikenen J.B., Binion D.G. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000, 95:3189-3194.
6. Cucchiara S., Morley-Fletcher A. "New drugs: kids come first": children should be included in trials of new biological treatments. Inflamm Bowel Dis 2007, 13:1165-1169.
7. Lionetti P., Bronzini F., Salvestrini C., Bascietto C., Canani R.B., De Angelis G.L., et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 2003, 18:425-431.
8. Vermeire S., Noman M., Van Assche G., Baert F., D'Haens G., Rutgeerts P. The effectiviness of concomitant immunosuppressive therapy in supressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007, 56:1226-1231.
9. Rutgeerts P., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402-413.
10. Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333.
11. Sandborn W.J., Hanauer S.B., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D.G., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC-II trial. Gut 2007, 56:1232-1239.
12. Colombel J.F., Sandborn W.J., Rutgeerts P., Kamm M.A., Yu A.P., Wu E.Q., et al. Comparison of two adalimumab treatment scheduled strategies for moderate-to-severe Crohn's disease:results form the CHARM trial. Am J Gastroenterol 2009, 104:1170-1179.
13. Panaccione R., Colombel J.F., Sandborn W.J., Rutgeerts P., D'Haens G.R., Robinson A.M., et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther 2010, Mar18, (Electronic publication ahead of print).
14. Karmiris K., Paintaud G., Norman M., Magdelaine-Beuzelin C., Ferrante M., Degenne D., et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009, 137:1628-1640.
15. Mian S., Baron H. Adalimumab, a novel anti-tumor necrosis factor-antibody in a child with refractory Crohn's disease. J Pediatr Gastroenterol Nutr 2005, 41:357-359.
16. Hadziselimovic F. Adalimumab induces and maintains remission in severe, resistant paediatric Crohn's disease. J Pediatr Gastroenterol Nutr 2008, 46:208-211.
17. Wyneski M.J., Green A., Kay M., Wyllie R., Mahajan L. Safety and efficacy of adalimumab in pediatric patients with Crohn's disease. J Pediatr Gastroenterol Nutr 2008, 47:19-25.
18. Rosembach Y., Hartman C., Shapiro R., Hirsch A., Avitzur Y., Shamir R. Adalimumab treatment in children with refractory Crohn's disease. Dig Dis Sci 2009, 55:747-753.
19. Noe J.D., Pfefferkorn M. Short-term response to adalimumab in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008, 14:1683-1687.
20. Viola F., Civitelli F., Di Nardo G., Barbato M.B., Borrelli O., Oliva S., et al. Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease. Am J Gastroenterol 2009, 104:2566-2571.
21. Rosh J.R., Lerer T., Markowitz J., Goli S.R., Mamula P., Noe J.D., et al. Retrospective evaluation of the safety and effect of Adalimumab therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol 2009, 104:3042-3049.
22. Mackey A.C., Green L., Liang L.C., Dinndorf P., Avigan M. Hepatosplenic T-cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007, 44:265-267.
23. Van Assche G., Magdelaine-Beuzelin C., D'Haens G., Baert F., Noman M., Vermeire S., et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008, 134:1861-1868.
24. Martín de Carpi J., Varea V. Response to stopping azathioprine in Crohn's patients on combined treatment with infliximab. An Pediatr(Barc) 2009, 70:271-277.